MHM Magazine

6 | MENTAL HEALTH MATTERS | 2022 | Issue 6 MHM A breakthrough therapy for your patients with treatment-resistant depression (TRD) 1 SPRAVATO®, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. 4 REFERENCES: 1. USFDA. Food and Drug Administration approves new nasal spraymedication for treatment-resistant depression; available only at a certi‹ied doctor’s of‹ice or clinic. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal- spray-medication-treatment-resistant-depression-available-only-certi‹ied.AccessedMay2022. 2. Harmer CJ, Duman RS, Cowen PJ. Howdo antidepressantswork?Newperspectivesforre‹iningfuturetreatmentapproaches. LancetPsychiatry. 2017May;4(5):409-418.3.HillhouseTM, PorterJH.Abriefhistoryofthedevelopmentofantidepressantdrugs:frommonoaminestoglutamate. ExpClinPsychopharmacol. 2015Feb;23(1): 1-21. 4. SPRAVATO® (esketamine) Approved Professional Information. 06 April, 2022. 5. Bozymski KM, Crouse EL, Titus-Lay EN, et al. Esketamine: A Novel Option for Treatment-Resistant Depression. Ann Pharmacother. 2020 Jun;54(6):567-576. 6. Popova V, Daly EJ, Trivedi M, et al. Ef‹icacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019 Jun 1;176(6):428-438. 7. Wajs E, Aluisio L, Holder R, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry. 2020 Apr 28;81(3):19m12891. S5 SPRAVATO® 28 mg nasal spray. Each nasal spray device contains esketamine hydrochloride equivalent to 28 mg esketamine. Registration number: 53/1.2/0732. For full prescribing information refer to the approved SPRAVATO® Professional Information (6 April 2022). JANSSEN PHARMACEUTICA (PTY) LTD/(EDMS) BPK; (Reg. No.:/Regnr.: 1980/011122/07); No 2, Medical Road, Halfway House, Midrand, 1685. www.janssen.com. Medical Info Line: 0860 11 11 17. CP-319977 The irst approved antidepressant in 30 years with a newmode of action 2,3,4 Statistically signi icant and sustained improvement versus antidepressant plus placebo 6,7 The irst nasal spray antidepressant 4,5 Rapid onset of action 6